Medline (MDLN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of 12 directors is up for shareholder vote at the 2026 Annual Meeting, with board recommendations provided for each nominee.
Advisory vote to approve executive compensation is included on the ballot.
Advisory vote on the frequency of future executive compensation votes is presented, with a 1-year frequency recommended.
Ratification of Ernst & Young LLP as independent auditor for fiscal year 2026 is proposed.
Proxies may vote on other matters arising at the meeting or any adjournment.
Board of directors and corporate governance
Twelve director nominees are listed for election, including Charles N. Mills, Joseph P. Baratta, and others.
Executive compensation and say-on-pay
Shareholders are asked to approve executive compensation through an advisory vote.
Advisory vote on the frequency of executive compensation votes is included, with a 1-year interval recommended.
Latest events from Medline
- All board nominees and proposals were approved amid strong growth and strategic investments.MDLN
AGM 202611 Jun 2026 - Strong Q1 growth, proactive quality management, and raised guidance highlight robust outlook.MDLN
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Strong growth and resilience driven by scale, innovation, and customer-focused execution.MDLN
46th Annual William Blair Growth Stock Conference3 Jun 2026 - Secondary sale of 60 million shares highlights strong growth, high margins, and no proceeds to the company.MDLN
Registration filing20 May 2026 - Q1 2026 sales up 10.7%–11% to $7.4B; margins fell, but full-year sales guidance was raised.MDLN
Q1 202612 May 2026 - 2025 saw double-digit sales growth, a public listing, and enhanced governance and ESG focus.MDLN
Proxy filing23 Apr 2026 - 2025 saw 11.5% sales growth, record signings, and IPO success, with strong 2026 outlook.MDLN
Q4 202516 Apr 2026 - 2026 outlook targets 8%-9% organic growth, margin expansion, and continued market share gains.MDLN
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - 75 million shares offered by selling stockholders; strong recurring revenue and growth outlook.MDLN
Registration Filing3 Mar 2026